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0022-2836 © 2008 Elsevier Ltd.Open acceMyosin binding protein C (MyBP-C) is a thick filament protein involved in
the regulation of muscle contraction. Mutations in the gene for MyBP-C are
the second most frequent cause of hypertrophic cardiomyopathy. MyBP-C
binds to myosin with two binding sites, one at its C-terminus and another at
its N-terminus. The N-terminal binding site, consisting of immunoglobulin
domains C1 and C2 connected by a flexible linker, interacts with the S2
segment of myosin in a phosphorylation-regulated manner. It is assumed
that the function of MyBP-C is to act as a tether that fixes the S1 heads in a
resting position and that phosphorylation releases the S1 heads into an
active state. Here, we report the structure and binding properties of domain
C1. Using a combination of site-directed mutagenesis and NMR interaction
experiments, we identified the binding site of domain C1 in the immediate
vicinity of the S1–S2 hinge, very close to the light chains. In addition, we
identified a zinc binding site on domain C1 in close proximity to the S2
binding site. Its zinc binding affinity (Kd of approximately 10–20 μM) might
not be sufficient for a physiological effect. However, the familial hyper-
trophic cardiomyopathy-related mutation of one of the zinc ligands, glu-
tamine 210 to histidine, will significantly increase the binding affinity,
suggesting that this mutation may affect S2 binding. The close proximity of
the C1 binding site to the hinge, the light chains and the S1 heads also
provides an explanation for recent observations that (a) shorter fragments of
MyBP-C unable to act as a tether still have an effect on the actomyosin
ATPase and (b) as to why the myosin head positions in phosphorylated
wild-type mice and MyBP-C knockout mice are so different: Domain C1
bound to the S1–S2 hinge is able to manipulate S1 head positions, thus
influencing force generation without tether. The potentially extensive extra
interactions of C1 are expected to keep it in place, while phosphorylation
dislodges the C1–C2 linker and domain C2. As a result, the myosin heads
would always be attached to a tether that has phosphorylation-dependent
length regulation.© 2008 Elsevier Ltd.Open access under CC BY-NC-ND license.Keywords: domain C1; NMR spectroscopy; model building; mutagenesis;
protein structureEdited by M. F. Summersess: mp84@le.ac.uk.
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The regulation of muscle contraction depends on
the precise interaction in time and space of a large
number of proteins. In vertebrate cardiac muscle, the
prime means of regulation is achieved by the well-
established calcium-dependent steric blocking and
unblocking of themyosin binding site on actin by the
troponin–tropomyosin complex. Unlike skeletale.
Fig. 1. Cartoon depicting current understanding of MyBP-C function. (a) Illustration of the expected effect of phos-
phorylation of the N-terminal myosin binding site that dislodges MyBP-C, releasing the S2 coiled coil and subsequently
promoting cross-bridge formation and muscle contraction. (b) A possible interpretation of the observation that MyBP-C
constructs too short to act as a tether can influence muscle contraction. In this interpretation, the N-terminus directly
affects the orientation of the myosin head group, indicated by the arrows. (c) Alternative interpretation where the effect of
an N-terminal fragment of MyBP-C is caused by an interaction with the thin filament. The coiled-coil part of myosin is
shown in red; S1, in light blue; MyBP-C, in dark blue; and F-actin, in green. For simplicity, several MyBP-C domains are
grouped in a single box. Phosphorylated residues are indicated by pink dots.
616 MyBP-C in the Regulation of Muscle Contractionmuscle, where force is regulated by recruitment of
activated fibres, modulation of the force levels in the
electrically coupled cardiomyocytes occurs by post-
translational modification of regulatory proteins,
especially phospholamban and troponin I.1 More
recently, several proteins that provide an additional
level of control in a more indirect and subtle manner
have emerged. Among these is the cardiac isoform of
myosin binding protein C (MyBP-C).2–4 MyBP-C
belongs to the family of sarcomeric multidomain
proteins that also includes titin, myomesin and
obscurin, all of which are believed to play an
important role in the assembly of different compo-
nents of the sarcomere—modulation of contractile
properties and mechanical strain sensing.5 For
MyBP-C, more and more data suggesting its more
prominent role in the regulation of muscle contrac-
tion are accumulating. Binding of the N-terminal
portion of MyBP-C to myosin close to the S1 head6 is
generally accepted to hold back the myosin headsFig. 2. Structure of domain C1 of human cardiac MyBP-C.
round of structure calculation. (b) Cartoon view of the best stru
orientation as in (a). (c) FHC-linked point mutations found in C
with a clear disease indication are shown in red, and those sh
are shown as a Van der Waals sphere for all to make the side-c
residues are shown in blue, and those for non-exposed residu
Strands A and A′ are hidden.and thus reduce their ability for interaction with
actin as observed by X-ray fibre diffraction and
electron microscopy7 (see Fig. 1a for illustration).
Tethering of the S1 heads via MyBP-C to the rest of
the thick filament reduces force development,8
which returns to normal once the tether is released
upon phosphorylation of MyBP-C9,10 (see Fig. 1a).
Malfunction of MyBP-C caused by missense or
truncation mutations is a well-known cause of
cardiomyopathies.11 After myosin itself, mutations
in MyBP-C are the second most frequent cause of
familial hypertrophic cardiomyopathy (FHC), sug-
gesting that MyBP-C does indeed play a vital role in
cardiac function.3 A vital yet subtle role for MyBP-C
in the regulation of cardiacmuscle was confirmed by
the analysis of knockoutmice.12 It was found that the
overall structure of the sarcomere was unaffected,
suggesting that MyBP-C is not required for sarco-
mere assembly, yet the knockout mice displayed
symptoms of cardiac hypertrophy. Detailed studies(a) Family of the best 29 structures resulting from the final
cture of C1 from the family of structures in (a) in the same
1 mapped on the structure of C1. Residues found mutated
own to be polymorphisms are shown in green. β-Carbons
hain orientation more evident. Labels for solvent-exposed
es are shown in black. The β-strands are labelled in white.
Fig. 2 (legend on previous page)
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rearrangements of the myosin heads but no signi-
ficant change in diameter.13,14 The latter finding is
surprising because large changes have been observed
as a result of phosphorylation,15 which is thought to
dislodge the MyBP-C N-terminus from its binding
site on S2.9 If MyBP-C functions mainly as a tether,
then the arrangements of myosin heads should be
comparable in phosphorylated wild-type (WT) and
knockout mice. The fact that they are very different
suggests MyBP-C functionality beyond that of a
mere tether. A more direct influence of the N-
terminus ofMyBP-C onmuscle contraction is indeed
supported by recent observations. Several studies
showed that N-terminal fragments too short to
perform the tethering function nevertheless had a
significant effect on myocardial contraction16,17
(possible interpretations illustrated in Fig. 1b and c).
The N-terminal myosin binding site of cardiac
MyBP-C consists of two immunoglobulin I (IgI)
domains,18 C1 and C2, connected by an ∼100-resi-
due linker of unknown structure containing the
phosphorylation sites. We recently determined the
structure and mapped the binding site of domain C2
onmyosin S2 using a shortened fragment of S2, S2Δ,
giving a first glimpse of the mode of binding of these
two proteins and how mutations related to FHC can
interfere.19 Here, we extend our investigation of this
interaction by determining the structure of domain
C1 and locating its binding site on myosin S2. The
results of our study on the binding of C1 and C2 to
myosin S2 are combined in a model for the inter-
action that agrees well with current understanding
of this system and its perturbation by mutations in
MyBP-C or myosin S2. The location of domains C1
and C2 is also highly suggestive as an explanation of
how the N-terminus of MyBP-C alone can affect
myosin activity.16,17 Furthermore, our work shows
that most FHC-related point mutations do not abo-
lish the MyBP-C-myosin interaction but weaken it,
reflecting the general observation that FHC-related
mutations in MyBP-C lead to late-onset FHC with
generally good prognosis.
Results
Structure of domain C1
The overall quality of the NMR structure is
apparent by the excellent agreement of the 29 struc-
tures shown superimposed in Fig. 2a, giving an
overall backbone RMSD of 0.6 Å. The only region
with modest disorder is around the last C-terminal
residues, which are already part of the linker that
connects C1 to C2. The domain folds as expected
into an all-β-sheet structure of the IgI fold,18 appa-
rent in Fig. 2b. Here, the structure is shown as a
cartoon in the same orientation as in Fig. 2a. Four
strands, ABED, form the first sheet and the remain-
ing five, C′CFGA′, form the second sheet, which are
assembled in a β-sandwich structure. The CD loop
in domain C1 is slightly extended compared withother IgI domains in MyBP-C (see Fig. S1). The extra
residues fold into a very compact structure, very
close to a single turn of an α-helix. The turn is
supported by an α-helix type of hydrogen bond
between the amide group of Val203 and the back-
bone carbonyl oxygen of Leu199.
Zn binding of C1
Close inspection of the structure of C1 revealed
the presence of a zinc binding site formed by
residues Gln208, His210, Glu223 and His225. These
four residues are arranged in a neat square right in
the centre of the A′BED β-sheet (Fig. 3a), two on β-
strand D and two on β-strand E, in a manner
similar to other zinc binding sites on the surface of
β-sheets.20 Titrations of 15N-labelled protein with
ZnCl2 were performed and monitored with the use
of fast-heteronuclear multiple-quantum coherence
spectra to experimentally ascertain the ability of
domain C1 to bind zinc.21 Large chemical shift
perturbations were observed (Fig. 3b) for two main
regions, residues 208–213 and residues 223–230,
covering very well the predicted zinc binding site.
The largest chemical shift perturbations were seen
for the two histidines in the predicted binding site,
suggesting strong zinc coordination by these two
residues (see Fig. 3c). A zinc atom was positioned
in the binding site followed by energy minimisa-
tion in AMBER22 using standard zinc parameters23
to test the relevance for further ligands. The re-
sulting distances suggest that the zinc is coordi-
nated by four ligands—Gln208, His210, Glu223 and
His225. Interestingly, the residues with the largest
chemical shift perturbations are titrating in the
slow-exchange regime, suggesting a slow off rate
and thus reasonably tight binding (spectra for
representative residues are shown in Fig. S2).
Titration curves plotted for some residues close to
the binding site in fast exchange are used for
analysis of binding affinity, as shown in Fig. 3d.
Fitting these curves leads to a dissociation constant
in the range of 10–20 μM, in good agreement be-
tween these residues.
Binding of C1 to myosin S2Δ
To probe the binding of C1 to S2Δ, we followed
essentially the same approach previously described
for domain cC2.19 A transverse relaxation-opti-
mized spectroscopy two-dimensional 15N–1H spec-
trum of C1 was recorded in the absence and in the
presence of a 4-fold excess of S2Δ (examples are
shown for several representative residues in Fig. S3).
To identify the binding site of S2Δ on C1, we plotted
the chemical shift differences for all assigned
residues against the sequence of C1 (Fig. 5, top,
blue curve). In this plot, three regions of chemical
shift perturbations clearly stand out: the region
around strands C, C′, the CD loop and parts of
strand D; the EF loop and part of β-strand E; and the
last three residues of β-strand G. Most prominent as
individual residues are Lys195 and Trp196. Map-
Fig. 3. Zinc binding of C1. (a) Detailed view of the zinc binding site in the structure of C1. Only side chains of Gln208,
His210, Glu223 and His225 are shown. A zinc atom has been modelled in the binding site. After energy minimisation, the
zinc-ligand distances are 2.27 Å for His210(Ne2), 2.26 Å for His225(Ne2), 1.60 Å for Glu223(Oe1), 1.81 Å for Glu223
(Oe2) and 2.22 Å for Gln208(Oe1). (b) Plot of chemical shift perturbation against the protein sequence. The first red line
represents the 〈Δδ〉tot level, and the second red line is 〈Δδ〉tot+1∗σ. Residues with chemical shift perturbations above
〈Δδ〉tot+1∗σ are explicitly labelled. (b) Titration curves for residues in fast exchange for estimating binding affinity and
stoichiometry. (c) Mapping of chemical shift perturbations on the three-dimensional structure of C1. Residues with
chemical shift perturbations above 〈Δδ〉tot+1∗σ are shown as spheres. The residues expected to coordinate the zinc are
shown in red (histidines) and blue (glutamate/glutamine), and those with significant perturbations not expected to be
directly involved are shown in green. (d) Titration curves for residues in fast exchange for estimating binding affinity
and stoichiometry.
619MyBP-C in the Regulation of Muscle Contractionping of the significant chemical shift perturbations
on the surface of the structure of C1 (Fig. 6a) shows
that the three regions, although disconnected in the
sequence, come together in the three-dimensional
structure. These residues form a continuous surface
covering most of the C-terminal half, from the CD
loop onward.Effects of FHC-related mutations in C1 on
binding to myosin
Several point mutations linked to FHC have been
identified in domain C1 of cardiac MyBP-C. They
are shown mapped on the structure of the domain
in Fig. 2d. For completeness, known polymorph-
Fig. 5. Chemical shift perturbations in titrations of 15N-
labelled C1 with unlabelled S2Δ. Shown are combined 15N
and 1HN chemical shift perturbations against the sequence
of C1. Top: C1 WT+S2Δ WT (blue), C1 WT+S2Δ E846K
(red) and C1 D228N+S2Δ WT (green). Bottom: C1 WT+
S2ΔWT (blue), C1 WT+S2Δ E924K (green), C1 WT+S2Δ
E936K (red) and C1 WT+S2Δ E894G (pink). The 〈Δδ〉tot
and 〈Δδ〉tot+1∗σ levels (0.021 and 0.042 ppm, respec-
620 MyBP-C in the Regulation of Muscle Contractionisms are also indicated. Among these is residue 236,
which in the construct used in this work is actually
a glycine.24 It is worth noting that most poly-
morphisms in human cardiac C1 are found in other
isoforms or species, confirming their compatibility
with the structure and function of C1 (Fig. S1). In
contrast, the majority of residues where mutations
correlate with disease are highly conserved, at least
in the cardiac isoform (e.g., Arg177, Tyr237 or
Val256). Most of the FHC-related mutations affect-
ing exposed amino acids cluster toward the C-
terminus of the domain (on the right side of Fig. 2c).
A smaller cluster of FHC-related mutants is formed
on the ABED sheet, close to the β-bulge in strand A
and far away from the S2Δ binding site. The
correlation of most FHC-linked mutations with the
location of the binding site of S2Δ suggests that at
least the solvent-exposed amino acids might con-
tribute to FHC by interfering with protein inter-
actions. To investigate this hypothesis, we selected
two mutants from this region, Asp228 to aspa-
ragine, representing exposed charged residues in
the binding site for S2Δ, and Tyr237 to serine,
representing mutations of non-exposed amino acids
close to the binding site. Tyr237 is strongly
conserved, and part of the hydrophobic core and
its replacement by a serine would remove sub-
stantial hydrophobic contacts, leading to desta-
bilisation of the fold. In contrast, there is no
indication that the replacement of Asp228 with
asparagine will affect the structure. The different
expectations for the effects of both mutants on theFig. 4. Expression trials of C1 mutants D228N and
Y236S. Pilot expression was performed in 5-mL cultures in
20-mL tubes using BL21∗ cells. Cells were grown at 37 °C
until reaching induction levels of cell density, after which
the temperature was dropped to 15 °C and protein
expression was induced overnight. Cells were harvested
by centrifugation and opened by sonication. Samples for
gel electrophoresis were taken of the soluble fraction after
centrifugation of the cell extracts. M, molecular mass
marker (Mark12, Invitrogen; molecular masses are given
in kilodaltons); 1, C1 D228N; 2, C1 Y237S. Expected posi-
tion of C1 is marked by an arrow.
tively) for C1 WT+S2Δ WT are shown as dark red
horizontal lines. The position of β-strands is indicated by
black bars.structure of C1 were confirmed by expression trials
of both mutants (Fig. 4). C1 Asp228Asn expressed
extremely well as a soluble protein (Fig. 4, lane 1).
In contrast, Tyr237Ser did not express as a soluble
protein at all (Fig. 4, lane 2). Efforts to refold this
mutant from inclusion bodies failed repeatedly. As
a result, only Asp228Asn could be studied with
respect to binding to S2Δ.
The Asp228Asn mutant of C1 is still capable of
binding to S2Δ (Fig. 5, top, green curve), with
almost the full chemical shift perturbations around
Trp196 as in WT. In contrast, in the other two
regions of largest chemical shift perturbations in
WT, residues around His210 on strand D and those
in the EF loop around Gln230, there is very little
response to binding. Also, the three amino acids at
the C-terminus show hardly any response (Fig. 6b).
Asp228 is located right in the middle of the EF
loop, such that its mutation to asparagine, leading
to the loss of negative charge, might lead to an
almost complete lack of binding ability in this part
of the interface. The Asp228Asn mutant of C1 is
still able to bind, albeit with only part of its
interface and consequently substantially reduced
affinity.
Fig. 6. The S2Δ binding site on C1 mapped by chemical shift perturbations on the three-dimensional structure. (a)
Binding of C1 to S2Δ. (b) Binding of C1 D228N to S2Δ. (c) Binding of C1 to S2Δ E846K. All residues with chemical shift
perturbations above 〈Δδ〉tot are labelled and have their N atoms displayed as spheres. Residues with Δδ values between
〈Δδ〉tot and 〈Δδ〉tot+1∗σ are shown in yellow, and those above 〈Δδ〉tot+1∗σ are shown in red. The β-strands are labelled
in white.
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binding to MyBP-C domain C1
A large number of point mutations contributing to
the development of FHC have been identified in
myosin (for databases, see Materials and Methods; a
summary on the structure of S2Δ is given in Fig. S4).
Previously, use of pointmutations has been successful
in mapping the binding site of MyBP-C domain C2 in
the vicinity of Arg870.19 We therefore used the same
approach in the hope that an FHC-related point
mutationmight be linked to the disease by interfering
with the binding of domain C1. The initial focus was
on the cluster of eight mutations of exposed amino
acids between residues 921 and 935. The majority are
either charge inversions or charge changes, suggest-
ing the cluster to be a potential protein–protein inter-
action site. Furthermore, the S2Δ mutant Glu924Lys
was shown to abolish binding to an MyBP-C frag-
ment containing domain C1.6 However, binding
experiments of isolated C1 with two representative
mutants, Glu924Lys and Glu935Lys, led to chemical
shift perturbations indistinguishable from those of
WT S2Δ (Fig. 5, bottom). As this region was the only
clearly discernible cluster of mutations in addition to
the region aroundArg870, we opted to systematically
mutate exposed residues mutated in FHC. The first
mutations tested were Glu846Lys and Glu894Gly, the
former being an FHC-relatedmutation in S2Δ and the
latter being a representative of a mini-cluster of mu-
tants immediately following the C2 binding site.
Figure 5, top and bottom, shows that the chemical
shift perturbations of C1 in a mixture with S2Δ
Glu894Gly are virtually identical with those observed
with the WT of S2Δ. In marked contrast, mutant
Glu846Lys led to a significant reduction in the
chemical shift perturbations. This reduction is non-
uniform, with perturbations around residues 190–210
comprising the CD loop and the D-strand dropping
significantly, even to almost noise level for some resi-
dues in the D-strand (Fig. 6c). In contrast, perturba-
tions around the EF loop were much closer to those
observed for the WT. C1 thus binds to S2Δ around
residue Glu846, but binding of C1 to the S2Δ E846K
mutant is not completely abolished but severely
compromised.
Model of C1 bound to S2Δ
Expanding the previous model of C2 bound to
S2Δ,19 we produced a model of the complex of C1–
linker–C2 (C1C2) with S2Δ. Use of the entire mini-Fig. 7. Model of the complex of C1 and S2Δ. (a) Overview o
with chemical shift perturbations larger than 〈Δδ〉tot are marke
of the interactions of C1 and S2Δ in the model. C1 is shown in
interaction are coloured by atom type (carbon, green; oxygen,
Depiction of the overall assembly of C1 and C2 and the link
orange, and the linker between them is shown in gray. The thr
residues mutated in FHC are shown in yellow with labels and
S2Δ is shown with solvent-accessible surface coloured by a sim
(hidden by C1) and the C-terminus on the right. The position o
S2Δ is indicated by the residue numbers (924–936).mal binding site of MyBP-C for S2 should aid in
identifying a realistic binding mode. Based on the
FHC-related mutation S2Δ Glu846Lys, which led to
a significant reduction in binding, domain C1 was
modelled to be in contact with this amino acid on
S2Δ, very close to the start of the S2 region at Pro838.
The interface in the model is formed by C1 aligning
with its β-strands almost in line with themain axis of
the coiled coil. The slope created by the crossing
helices is well covered in shape by the extended
loops at the C-terminus of C1, which generate an
interface of complementary shape (Fig. 7a). This
arrangement covers most of the amino acids with
significant chemical shift perturbations in the C1–
S2Δ interaction experiments very well. At the heart
of the interface sits the residue with the largest
chemical shift perturbations, Trp196. Together with
Ala232, it forms a small hydrophobic patch that
packs to Phe856 and Met852 on S2Δ. Furthermore,
the backbone oxygen of Trp196 makes a hydrogen
bond with the side chain of Arg845. The rest of the
interface is composed of polar interactions, even
though the charge distribution is much more mixed
compared with the C2–S2Δ interface.19 Right next to
the Trp196 is Lys195, which forms an ionic bridge
and/or a hydrogen bond with Glu848. The previous
residue, Gly194, forms a hydrogen bond with its
backbone oxygen to the side chain of Lys847. On the
other side of the central tryptophan, Asp198 interacts
with Lys841 via an ionic bridge and/or a hydrogen
bond. Lys202 in the following single turn of α-helix
forms another ionic bridge and/or a hydrogen bond
with Glu844. At the end of the CD loop, Gln205
makes a hydrogen bondwith Glu846 and potentially
with Lys847. The final residue on this stretch of
protein involved in the interface is His206, which
forms a hydrogen bond with Glu846. In the EF loop,
Gln230 forms hydrogen bonds with Glu854. Impor-
tantly, Asp228 forms an ionic bridge and/or a
hydrogen bond with Lys853, which will be signifi-
cantly weakened in the FHC-causing Asp228Asn
mutant. Finally, the very last residue of C1, Glu258, is
positioned to make a hydrogen bond with Thr857.Discussion
Structure of domain C1
The structure of C1 conforms to the well-estab-
lished pattern for the IgI fold,18 including the oncef the position of C1 (blue) on S2Δ (red). Amino acids in C1
d by green spheres on their N positions. (b) Detailed view
blue, and S2Δ is shown in red. Important side chains in the
red; nitrogen, blue), and labels are coloured by protein. (c)
er on S2Δ. Domains C1 and C2 of MyBP-C are shown in
ee phosphorylation sites in the linker are shown in purple,
charged residues are coloured according to their charge.
ple electrostatic potential with the N-terminus on the left
f the C-terminal cluster of FHC-related point mutations in
Fig. 7 (legend on previous page)
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troduced through a small extension of the CD loop, a
feature unique to domain C1 and seen in the NMR
structure of the slow skeletal isoform of domain C1 as
well [Protein Data Bank (PDB) code 2dav; Fig. S5].
The structure overall is rather extended, much longer
than, for example, the adjacent domain C219 and very
similar to the recently published crystal structure.26
Comparison with DaliLite gives an RMSD of 1.8 Å
and a z score of 13.2. The only structural differences
are found in the termini and some loops (e.g., the BC
loop). In the crystal structure, the first five residues
extend away from the protein, stabilised by crystal
contacts while they pack tightly to the rest of the
protein in the NMR structure. The most similar
structures found through a DALI search27 in the PDB
are those of the slow skeletal muscle isoform of
human MyBP-C, the well known telokin and the first
and second IgI domains of human cardiac titin. Car-
diac and slow skeletal isoforms of domain C1 share a
sequence identity of 53% (for more details, see Table
S1) such that a highly similar structure is not
surprising. Main sequence differences exist in the
BC loop, the EF loop and close to the C-terminus (see
Fig. S1). These variations are reflected in the structure
where the BC loop is packing very closely to the N-
terminus in the cardiac isoform, whereas it is shifted
toward the DE hairpin in the slow skeletal isoform.
Overall, however, the structures are extremely
similar such that the substantial sequence divergence
between the isoforms has no impact on the detailed
structure. This is not surprising, as most of the con-
served amino acids are the key hydrophobic residues
important for determining the fold.18 Most of the
divergent amino acids are found on the surface of the
protein, suggesting subtle functional differences (e.g.,
with regard to binding partners).
Zinc binding of C1
The zinc binding site exhibits very similar struc-
ture and topology in employing two amino acids
each on adjacent β-strands (Fig. 3a) to a variety of
otherwise completely unrelated structures.20 The
arrangements of ligands are identical in the NMR
and X-ray structures. Interestingly, the composition
of amino acids in the binding site, His–His–Glu–Gln,
is typical of zinc binding in metalloenzyme active
sites. Taken together with the appreciable binding
affinity in the lower micromolar range, this makes
C1 a bona fide zinc binding domain. Zinc binding in
enzyme active sites occurs with affinities from
picomolar to micromolar,28 while it is even higher
when it fulfils a structural role.29 In the context of
cardiac muscle, however, the presence of a zinc
binding site with micromolar affinity is surprising.
Measurements of free zinc concentration in rat
cardiac muscle show values of less than 1 nM,
even under extreme cell stress,30 such that the affi-
nity of C1 is too low to bind zinc in vivo. One could
make some allowance for the underestimation of
binding affinities by NMR spectroscopy and for
different zinc concentrations in human cardiacmuscle compared with rat, but a variation by several
orders of magnitude seems unlikely. Given the usual
specificity of zinc binding sites, it is also unlikely
that this binding site could bind other metals. Ins-
tead, we expect the zinc binding site to become
physiologically relevant by the mutation of Gln208
to histidine, which is linked to FHC by an as yet
unknown mechanism.31 Gln208 is one of the four
zinc-coordinating ligands and shows significant
chemical shift perturbations in the zinc titration.
However, glutamines are known to contribute much
less as zinc ligands, such that a replacement by
histidine is expected to strongly increase the affinity,
which would allow for zinc binding in cardiac
muscle. Because of the very low concentration of
free zinc, even a modest sequestration of zinc might
have pathological consequences. The effect could
also be more direct because the zinc binding site
partly overlaps with the S2Δ binding site. As a
result, having zinc bound in part of the S2Δ binding
site might influence the interaction.
Interaction of C1C2 and S2Δ
The results of the interaction experiments between
C1 and S2Δ, including the respective mutations, are
well summarised in the model of the complex. The
amino acids of C1 showing the largest chemical
shift perturbations are well covered by the interface
(Fig. 7a) and involved in hydrogen bonds/ionic
interactions (Fig. 7b). This is only a model based on
chemical shift perturbations combined with muta-
genesis. Yet, many details agree well with the NMR
observations and can explain why a number of
residues mutated in FHC may cause the disease
(Fig. 7b). Residue Glu846 is involved in a hydrogen
bond and/or an ionic bridge and when replaced by a
lysine will weaken the interaction considerably, in
particular around the C-terminus of the CD loop
(residues 202–208), while the core interactions
around W196 and the EF loop are maintained (Fig.
7b). Also, the last residue in the C1 construct, Glu258,
is an FHC-related residue when mutated to lysine. In
our model, Glu258 forms a hydrogen bond with
Thr857, which will be abolished by a lysine. Even
though this interaction was not investigated experi-
mentally because Glu258 is not very well defined in
the structure and not part of domain C1 but of the
C1–C2 linker, we can clearly reveal its importance in
our model. It can be assumed that the nearby
mutation His257Pro would have similar consequen-
ces. We do not see any direct interactions of His257
with S2Δ, but a proline in its place would distort the
backbone at this position, resulting in repositioning
Glu258 in a manner not conducive to the interaction
with Thr857. This mutation could also have long-
range effects, because it is located in a place where C1
and C2 are almost in touching distance, exemplified
by the interaction of Arg858 of S2Δ with Asp431 in
C2, right next to the interaction of Thr857 with
Glu258 in C1.
The effects of the FHC-relatedmutations in C1 that
were experimentally investigated here, Tyr237Ser
625MyBP-C in the Regulation of Muscle Contractionand Asp228Asn, can also be explained in this
context. While the mutation of Tyr237 to serine led
to the unfolding of the domain, the other point
mutation, Asp228Asn, did not interfere with folding
at all, as expected. Instead, the Asp228Asn mutant
severelyweakened the interaction of C1with S2Δ, as
would be expected based on our complex model.
Asp228 forms an ionic bridge and/or a hydrogen
bond with Lys853, which will be much weakened by
replacing the negatively charged aspartate with an
uncharged asparagine. The latter would still be able
to form a hydrogen bond, but this interaction would
be much weaker. This is confirmed by the chemical
shift perturbations measured in the Asp228Asn
mutant, where almost all chemical shift perturba-
tions in the EF loop are absent, while binding is
still maintained by the interactions made by the CD
loop, as well as other parts of the binding site.
Intriguingly, two further solvent-exposed amino
acids that are FHC related when mutated,
Arg177Cys and Val219Leu, are distant from the
S2Δ binding site. Yet, being on the surface, it is
unlikely that they would interfere with the domain
stability like Tyr237Ser. This suggests that C1 could
be involved in other interactions, as these residues
are close together on a part of the surface pointing
away from S2Δ, which is thus accessible for other
ligands. In our model, this part of the protein points
toward the S1–S2 junction close to the regulatory
light chains. Hence, C1 could directly or indirectly
be involved in an interaction with the myosin head
group. This may provide us with a possible
explanation why untethered N-terminal MyBP-C
fragments have significant effects in motility
assays,16,17 as illustrated in Fig. 9a.
In this work, we have modelled the position of
both IgI domains of MyBP-C's N-terminal binding
site on myosin that begs the question of the location
of the linker (MyBP-C motif). Recently, the linker
was proposed to be an IgI domain as well,32 which
appears very unlikely, given the low sequence
similarity of the linker sequence to Ig sequences.
Furthermore, these observations are in direct con-
trast to our own NMR data on the whole C1C2
fragment, which show the linker to be completely
unstructured (Fig. 8a). All residues of the linker are
in the random-coil region of the spectrum. Addi-
tionally, in a heteronuclear nuclear Overhauser
enhancement (NOE) experiment, the highest value
for residues in the linker was 0.2, while the residues
of domains C1 and C2 had values around 0.8 (Fig.
8b). One would expect residues in a rigid, well-
folded domain to have values between 0.7 and 0.9,
while values close to zero are indicative of almost
complete freedom of motion as expected of an
unfolded polypeptide chain. As both the small-angle
X-ray scattering and our NMR experiments were
performed with bacterially expressed protein, meth-
odological differences in protein folding can be
excluded. We therefore propose that the linker is
unfolded in solution but adopts a compact shape,
similar to other unstructured peptides (e.g., the
extensively characterised α-synuclein). This proteinis intrinsically unstructured yet has been shown by a
variety of NMR methods to adopt a compact overall
shape.33,34 This would enable it to adopt a more
defined conformation upon binding to myosin. We
do not have experimental data as yet about the
binding mode of the linker but at least endeavoured
to ensure that the positions of C1 andC2 in themodel
allow a location of the linker in accord with
published interaction data. In our extended model
(Fig. 7c), the positions of C1, C2 and the linker on S2
are indicated. The positions of C1 and C2 are such
that the linker runs along S2 to reach the area around
residue 930 of S2Δ. Here, we find a cluster of FHC-
related point mutations, one of which, E924K, makes
binding of C1C2 to S2Δ undetectable by isothermal
titration calorimetry.6 As neither C2 binding nor C1
binding to S2Δ is affected by this mutation, this part
of S2Δ likely interacts with part of the linker. The
linker can easily reach this part of S2 in our model,
even though we cannot make comments about
detailed interactions. It is conceivable, however,
that the linker does not adopt a precise, stable and
rigid conformation with very specific interactions.
Instead, the contribution from the linker to binding
might come from general charge complementarity.
Retaining a certain degree of mobility might add to
complex stability by reducing the entropic penalty
otherwise unavoidable for folding upon binding.
This mode of binding is not unusual and has been
observed (e.g., in the interaction of microbial
proteins with host receptors).35 The general charge
matching would also suggest an explanation for the
effect of phosphorylation upon binding: all three
serines known to be phosphorylated36 are positioned
in the vicinity of negatively charged patches on the
surface of S2. Phosphorylation would subsequently
lead to increased charge repulsion and consequent
destabilisation of the complex in accordance with
experimental observations.9 That the linker/MyBP-
C motif might bind alternative ligands when under-
going phosphorylation-induced conformational
changes is another possibility to explore.
Conclusions
Our combined NMR and mutagenesis data place
the N-terminus of MyBP-C right on top of the S1–S2
hinge and thus in immediate vicinity of the S1 head
and the light chains. In this location, MyBP-C is able
to directly interact with the hinge, potentially
influencing the positioning of the S1 heads directly
or indirectly via interactions with the light chains
(Fig. 9a). Such an interaction could also involve the
as yet relatively uncharacterised domain C0, which
is specific for the cardiac isoform. The ability to
manipulate the S1–S2 junction would give MyBP-C
the potential to directly adjust the position of the S1
heads and thus subtly influence muscle contraction.
With further interactions possible for domains C1
and C0 in the S1/light chain region, one could
expect that phosphorylation of the C1–C2 linker
does not dislodge the MyBP-C N-terminus comple-
tely. While the linker and possibly domain C2 will
Fig. 8. NMR of 15N-labelled con-
struct C1C2, corresponding to resi-
dues 151–451 of human cardiac
MyBP-C. (a) Heteronuclear single-
quantum coherence spectrum of
C1C2 (blue) superimposed with the
spectra of C1 (black) and C2 (red).
(b) Sections of a heteronuclear
1H–15N NOE experiment (green) of
C1C2 superimposed on its reference
experiment (blue) together with the
spectra of C1 (black) and C2 (red).
Peaks of the linker showing very
weak NOEs around zero are indi-
cated by arrows.
626 MyBP-C in the Regulation of Muscle Contractiondissociate, the more N-terminal part might remain
attached (Fig. 9b). The dissociation of a substantial
part of polypeptide chain will allow the release of
the myosin head and facilitate actomyosin cross-
bridge formation. At the same time, the remainingpart of MyBP-C is well positioned to exert a subtle
influence on the position of the S1 heads. Maintain-
ing a loosely tethered state would also be useful
through increasing the probability of rebinding once
the C1–C2 linker is dephosphorylated and the S1
Fig. 9. Summary of the results. (a) Potential effects of C1 binding close to the hinge and the light chains. Interactions of
C1 could either bring the heads closer or drive them farther apart as indicated by the arrows. These effects could occur
symmetrically or asymmetrically. (b) As a consequence of C1 binding to the S1–S2 hinge domain, C1 and the region
further N-terminal might remain bound even whenMyBP-C gets phosphorylated. C2 binds weaker than C1 and could be
dislodged with the C1–C2 linker, thus only lengthening the leash without ever completely unleashing the S1 heads. The
coiled-coil part of myosin is shown in red; S1, in light blue; MyBP-C, in dark blue; and F-actin, in green. For simplicity,
several MyBP-C domains are summarised in a single box. Phosphorylated residues are indicated by pink dots.
627MyBP-C in the Regulation of Muscle Contractionheads need to return to their resting positions. The
myosin heads are thus never taken off the leash, but
the length of the leash is adjusted by phosphoryla-
tion. As such, our data provide a good explanation
for the observations that MyBP-C has functions
beyond those of a simple tether and that its influence
on the structure of the S1 heads is more complex
than can be explained by a simple on/off model
driven by phosphorylation.Materials and Methods
Sample preparation
Domain C1 of human cardiac MyBP-C (residues 151–
258 of UniProt entry Q14896/MYBPC3_HUMAN) was
cloned as previously described24 into pET8c vector.
Protein expressed in this vector had a non-removable
histidine tag of sequence MHHHHHHSS attached to the
original sequence. For the zinc binding experiments, a
histidine-tag free construct of C1 was produced by cloning
into pETM-11 (EMBL Protein Expression Laboratory) with
the original construct as template using PCR and adding
NcoI/BamHI restriction sites to the construct. The cons-
tructs for S2Δwere identical with those used previously in
the crystal structure determination.37 All mutants of C1and S2Δ used in this work were created using Quik-
Change (Stratagene), following the standard protocol.
Proteins were overexpressed as described previously24
using the commercial bacterial host BL21∗ (Invitrogen).
Proteins were purified using FastFlow6 histidine binding
resin (GEHealthcare) in gravity flowmode as capture step
followed by gel filtration on a preparative Sephadex 75 16/
60 column (GE Healthcare). Samples were exchanged into
NMR buffer using either dialysis with Slidalyzer cassettes
(Pierce; volume=3–12 mL; cutoff=3 kDa) or NAP10 gel-
filtration columns (GE Healthcare). Samples were concen-
trated for measurement using VivaSpin 20 concentrators
(VivaScience) with a 5-kDa (C1) or 10-kDa (S2Δ) molecular
mass cutoff.
Structure determination of C1
Protein concentrations were 0.8 mM. Structure calcula-
tion and all other NMRwork reported here are based on the
previously published NMR assignment,24 available from
BMRB with accession code 6015. Structure calculation was
based on high-quality 15N- and 13C-resolved three-dimen-
sional NOE spectroscopy spectra recorded with a mixing
time of 100 ms on a 600-MHz Bruker DMX spectrometer.
The spectra were recorded on a protein sample of 0.8mM in
a buffer of 20 mM sodium phosphate, pH 7.0, 50 mMNaCl,
2 mM DTT, 1 mM ethylenediaminetetraacetic acid and
0.02% NaN3. Constraints used in the structure calculation
Table 1. Structure calculation statistics for the NMR
structures of domain C1
NMR constraints
Total NOEs 2920
Initial unambiguous distance constraints 320
Final list of distance constraints from ARIA 1796
Hydrogen-bond restraints 42
Dihedral restraints 132
Number of violations
NOE distance restraints N0.5 Å 0.0
Hydrogen-bond restraints N0.3 Å 1.43±1.05
Dihedral restraints N5 2.02±0.75
RMSD from idealized geometry
Bonds (Å) 0.0067±0.0004
Angles (°) 0.71±0.03
Dihedrals (°) 23.5±0.6
Improper (°) 0.80±0.05
Energy
Van der Waals (kcal/mol) −865.3±119.0
Electrostatic (kcal/mol) −4015.9±86.3
Ramachandran analysis (%)
Residues in most favored regions 78.6
Residues in allowed regions 17.3
Residues in generously allowed regions 3.8
Residues in disallowed regions 0.3
Coordinate precision (all residues, Å)
Backbone atoms 0.60±0.08
Heavy atoms 0.99±0.09
628 MyBP-C in the Regulation of Muscle Contractionare listed in Table 1. Dihedral constraints were produced
with TALOS,38 and distance constraints were taken from
manually picked peaks in the NOESY spectra. Structure
calculation was performed using a protocol identical with
that of domain C219 using ARIA 1.2.39 The coordinates of
the structure are available from the PDB with accession
code 2AVG.
Sequence analysis
Sequences similar to domain C1 of the cardiac isoform
of human MyBP-C were identified using BLAST40 to
search in the UniProt Knowledgebase database with
standard search parameters. Hits representing MyBP-C
were selected, and the corresponding regions were taken
from the respective full-length database entries. Selected
sequences were aligned using ClustalW41 and displayed
using ClustalX.42 Colouring was done using the same
thresholds as previously described.19
Mutants linked to FHC were extracted from publicly
available databases: the DNA Mutation Database for
Familial Hypertrophic Cardiomyopathy† and the more
general Sarcomere Protein Gene Mutation Database‡.
C1–S2Δ interaction
All NMR experiments were measured in 40 mM
phosphate, pH 7.0, 50 or 100 mM NaCl, 2 mM DTT and
0.02% NaN3. Sample concentration was 200 μM for
15N-
labelled C1 and was 800 μM for unlabelled S2Δ, at a ratio
of 1:4. 1H–15N transverse relaxation-optimized spectro-
scopy spectra43 were recorded for free C1 and the mix of
C1 and S2Δ 1:4 on a Bruker DMX spectrometer at
800 MHz equipped with a cryoprobe. Acquisition and
processing were done with TOPSPIN 1.3 and 2.0. The
appropriate volumes of C1 and S2Δ stocks were pipetted
in a VivaSpin 20 concentrator with a 5-kDa cutoff and
concentrated down to a volume of 400 μL, which was then
transferred into a 5-mm NMR tube (Shigemi) without
plunger, to prepare samples of C1–S2Δ mixtures. Deuter-
ium lock was achieved using 5% D2O in the sample. Prior
to each experiment, the pH value was adjusted to b0.1
deviation of the target of 7.0. Peaks were automatically
picked in all spectra and assigned using the published
assignment of C1. Chemical shift differences, Δδ, were
measured for both 15N and 1H and combined using a
scaling factor of 1.0 for 1H and that of 0.15 for 15N. NMR
analysis was performed with the analysis software of the
CCPN initiative.44 The average of the combined Δδ values
for the interaction of C1 WTwith S2ΔWTwas calculated
to give the standard deviation 1∗σ.
Zinc binding
NMR titrations were performed in 40 mM cacodylate,
pH 6.4, 100 mM NaCl, 2 mM DTT and 0.02% NaN3.
Protein concentration was 450 μM, and chemical shift
changes were monitored on a Bruker DMX spectrometer
at 600 MHz using fast-heteronuclear multiple-quantum
coherence experiments.21 The zinc was used as ZnCl2 in a
stock solution of 10 mM in the respective buffer and pH
level of which the appropriate amount was added at each†http://www.angis.org.au/Databases/Heart/
‡http://genetics.med.harvard.edu/~seidman/cg3/
index.htmlstep of the titration to the sample. The sample had a
volume of 400 μL in an NMR tube (Shigemi) minus the
insert. Steps used in the titration were (C1/Zn concentra-
tion ratios): 1.0:0.0, 1.0:0.2, 1.0:0.4, 1.0:0.6, 1.0:0.8, 1.0:1.0,
1.0:1.2, 1.0:1.4 and 1.0:1.8. Spectra were processed with
TOPSPIN 2.0 and analysed in CCPN analysis.44 After peak
picking and assignment, a series of experiments was
created. With the use of the “follow shift change” function,
peaks of the same amino acid along the titration were
automatically grouped. Tables of chemical shift change
versus zinc concentration or concentration ratio were then
constructed and exported for further analysis in Mathe-
matica 5.0 (Wolfram Research). Chemical shift perturba-
tion versus zinc concentration curves were fitted against a
standard binding isotherm:
δ =
δbound
h
Zn½  + C1½  +Kdð Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Zn½  + C1½  + Kdð Þ24 Zn½  C1½ 
q i
2 C1½ ð Þ
Chemical shift mapping was performed by calculating
combined chemical shift differences, Δδ, for both 15N
and 1H using a scaling factor of 1.0 for 1H and that of
0.15 for 15N based on the first experiment and the last
experiment in the series. The average of the combined Δδ
values over all residues was calculated to give the stan-
dard deviation 1∗σ.
Model building
The model of the C1–S2Δ interaction was modelled in
the context of the whole fragment, C1C2 bound to S2Δ.
The position of C2 on S2Δ was used as published pre-
viously.19 The model of the C1C2 complex with S2Δ was
generated in three consecutive stages: (1) knowledge-
based molecular docking using HADDOCK,45 (2) mole-
629MyBP-C in the Regulation of Muscle Contractioncular dynamics (MD) simulation trajectory calculations
using AMBER22 and (3) energy minimisation of the final
model structures using AMBER and ranking of the
complex models. This protocol scheme was used in an
iterative manner to reach the best final complex model:
Stage 1: We produced the complex models of C1C2–
S2Δ using the previously reported C2–S2Δ complex
interface to lock C2 on S2Δ;19 all the binding site
residues of C1 were used as follows: active and passive
residues (shown as red and yellow spheres, respec-
tively, in Fig. 6a); all residues of the linker between C1
and C2 were used as active and flexible; the residue
region used as the binding site on S2Δ was from P383
to E861; and all S2Δ residues except the region between
D945 and A962 were used as flexible.
Stage 2: We calculated short MD trajectories, 200–
400 ps, for the best three to five complex models
obtained from stage 1. This provides more structural
rearrangements between C1C2 and S2Δ and better
conformational space sampling of the complex. All the
MD simulations were performed in explicit TIP3P
water, the complex charge was neutralized by adding
Na+ ions, the time step was 1.5 ps and the temperature
was 300 K.
Stage 3: We minimised the complex structure models
and ranked them according to the number of residues
that are involved in the interface between C1 and S2Δ
by making hydrogen bonds and/or salt bridges. The
final best two or three complex models are then
subjected to another full run through stage 1 to stage 3.
We repeated this cycle five times before no further im-
provementwas achieved. The final best complexmodelwas
used for further structural analysis, as shown in Results.NMR of C1C2
NMR experiments were recorded on a 0.4 mM 15N-
labelled sample of C1C2 in 20 mM phosphate, pH 7.3,
50 mM NaCl, 2 mM DTT, 1 mM ethylenediaminetetraa-
cetic acid, 0.02% NaN3 at 800 MHz and a temperature of
303 K. In-house-modified Bruker standard pulse pro-
grams were used to record the heteronuclear single-
quantum coherence and the heteronuclear NOE experi-
ments. The latter was recorded with a 3.5-s saturation
period in a 5-s relaxation delay. Saturation and non-
saturation spectra were collected in interleaved mode.Accession code
The coordinates of the structure are available from the
PDB with accession code 2AVG.Acknowledgements
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